---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024273"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:32:33.801822+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk

## Summary
- Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.
- Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.
- Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).
- Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.
- Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases.

## SEC filing metadata
- accession: 0001493152-25-024273
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/0001493152-25-024273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024273
- JSON: https://secwatch.observer/filing/0001493152-25-024273.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.